Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TERT | O14746 | 2/20 | 0.70 |
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.70 |
| ▸ | IKBKB | O14920 | 1/20 | 0.70 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311865 | 0.89 | TERT (0.68) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL910079 | 0.86 | CYP1A2 (0.64) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL30623128 | 0.84 | TERT (0.71) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| 7,8-Dihydroxyflavone SCHEMBL419316 | 0.83 | TERT (1.00) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| 7,8-Dihydroxyflavone SCHEMBL29374601 | 0.83 | TERT (1.00) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL27676687 | 0.82 | CYP1A2 (0.65) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL1516397 | 0.81 | CYSLTR1 (0.78) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| 7,8-Dihydroxyflavone SCHEMBL21852713 | 0.81 | TERT (0.97) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL22032708 | 0.81 | CYP1B1 (0.63) | CYP19A1MAPTCYP3A4HPGDTP53 | |
| SCHEMBL4649417 | 0.81 | CYP1B1 (0.63) | CYP19A1MAPTCYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| CN-113046333-B | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2023-02-17 | — | — | CN | claimed |
| CN-113046333-A | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2021-06-29 | — | — | CN | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| CN-118995656-A | Demethylation functional enzyme of flavonoid compound, and encoding gene and application thereof | 上海中医药大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| CN-113046333-B | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-113046333-B | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-113046333-B | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-113046333-A | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2021-06-29 | — | — | CN | disclosed |
| CN-113046333-A | Flavone-8-hydroxylase and application thereof in synthesis of 8-hydroxyflavone compound | 中国科学院天津工业生物技术研究所 | 2021-06-29 | — | — | CN | disclosed |
| US-4889941-A | Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase | FISONS CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4797498-A | Flavonoxypropanolamines and esters of flavonoxypropanolamines as antiarrhythmic agents | PENNWALT CORPORATION (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0288077-A2 | Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase | PENNWALT CORPORATION (US) | 1988-10-26 | — | — | EP | disclosed |
| US-4780478-A | Aminopropoxy-chromones useful as antidepressants | MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) | 1988-10-25 | — | — | US | disclosed |
| US-4508732-A | Basic ethers useful as antidepressant agents | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-04-02 | — | — | US | disclosed |
| EP-0031885-B1 | BASIC ETHERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | MERCK PATENT GmbH (DE) | 1984-06-27 | — | — | EP | disclosed |
| US-4376123-A | Hexahydroazepinyloxy-chromones useful as antidepressants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-03-08 | — | — | US | disclosed |
| EP-0031885-A1 | Basic ethers, pharmaceutical compositions containing them and process for their preparation | MERCK PATENT GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | CYP19A1 2295/4885MAPT 3238/4885CYP3A4 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.